Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis

NCT05881785 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05881785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05881785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis
Lead sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2022
Completion date
May 21, 2024
Enrollment
465 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis